Navigation Links
Max Neeman Develops Innovative Approach for Rare Disease Studies
Date:3/1/2011

RESEARCH TRIANGLE PARK, N.C., March 1, 2011 /PRNewswire/ -- Max Neeman International has established a team of experts specialized in carrying out rare disease trials in response to sponsor demand. The team has the required expertise to develop innovative approaches to optimize complex study design.  Often strict inclusion/exclusion criteria and data analysis for rare disease studies create the greatest challenge for Biotech and Pharma that the company's expertise can address.

(Logo: http://photos.prnewswire.com/prnh/20110105/CL25129LOGO)

Max Neeman is a leading CRO in India that has a focus on Rare Disease Studies, in addition to other indications.  Patient enrollment for rare disease, complex global and multi-centric trials is challenging because potential subjects are fewer in number and widely dispersed.  India has evolved into a preferred destination for conducting such trials because of low cost and faster patient recruitment supported by the country's diverse gene pool and vast population of 1.3B.

Rare diseases are frequently life-threatening or chronically debilitating. However, drug development for these conditions has been limited by relative unavailability of subjects for clinical trials, as well as the high cost of investing in a novel pharmaceutical agent with poor market potential.  

Max Neeman International conducts India-based clinical research services for clients across the globe delivering quality results and exceptional customer service at a lower cost resulting in high client satisfaction.

About Max Neeman International

Max Neeman International is one of the leading and largest CROs in India and the clinical research arm of healthcare conglomerate, Max India.  Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company has 6 regional offices and 175 sites across 31 cities. Contact Donald Swankie, Vice President USA via email to donald.swankie@neeman-medical.com or call +1.919.424.3345.  www.neeman-medical.com

About Max Healthcare

Also part of the Max India group, Max Healthcare is one of a leading chain of hospitals in India.  State of the art infrastructure, India/Europe/USA trained physicians, and most advanced technologies make it one of the best hospitals in the country. www.maxhealthcare.in


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Max Neeman International Expands Specialized Surgical Team for Clinical Trials
2. Max Neeman International and AMEDON Collaborate to Increase EDC Performance
3. Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model
4. Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
5. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
6. Max Neeman International ISO 27001:2005 Certified for Information Security Management Systems
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Nventa Develops Proprietary Vaccine Adjuvant
9. Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
10. Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures
11. Binghamton Research Group Develops New Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Jan. 18, 2017   Seno Medical Instruments, Inc. ... breast cancer through the development of an opto-acoustic (OA/US) ... Miller as SVP of Engineering. Mr. Miller previously ... FUJIFILM SonoSite, with headquarters in Bothell, Washington ... his 30-year career to the development of innovative medical ...
(Date:1/18/2017)... Jan. 18, 2017  Tarix Orphan LLC today announced ... a Rare Pediatric Disease (RPD) designation for the company,s ... Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. There ... is limited to supportive care. "The RPD ... Designation previously granted by the FDA in this indication," ...
(Date:1/18/2017)... January 18, 2017 After the recent ... the use of cannabis both for medical and recreational purposes ... Americans open to the use of cannabis, but the focus ... to Arcview Market Research, the North American legal cannabis market ... the previous year. The research projects sales will grow at ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... ... SunView Software’s Service Smart Technology has been selected as a finalist for ... year, Pink Elephant recognizes a new product or service developed by an IT services ... opportunity. The award highlights original innovations that were released in 2016, either as a ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... at the National Association of Music Merchants (NAMM) winter trade show, Booth #2876, ... , Etymotic’s ER•4® has long been the gold standard for high-definition, in-ear earphones. ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... as well as Palm Desert, is opening a new office in San Clemente, ... transcranial magnetic stimulation (dTMS) in Southern California, successfully treating individuals struggling with major ...
(Date:1/17/2017)... ... 17, 2017 , ... Medic-CE , a Career Step ... has released four new continuing education courses as part of its Code3 CME ... online classroom and meet the requirements of the National Continued Competency Program (NCCP), ...
(Date:1/17/2017)... ... 17, 2017 , ... Surgeons from New York’s fastest growing ... on the latest breakthroughs in the prevention, diagnosis and treatment of the most ... eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of SightMD and Managing ...
Breaking Medicine News(10 mins):